Skip to main content
SK biopharmaceuticals Co., Ltd. logo

SK biopharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 326030 ISIN · KR7326030004 LEI · 9845004573839986EA59 KO Manufacturing
Open in API
Filings indexed 345 across all filing types
Latest filing 2026-05-19 Investor Presentation
Country KR South Korea
Listing KO 326030

About SK biopharmaceuticals Co., Ltd.

https://www.skbp.com/

SK biopharmaceuticals is a pharmaceutical company focused on the research, development, and commercialization of innovative treatments, primarily for central nervous system (CNS) disorders. The company's portfolio is led by Cenobamate, an anti-seizure medication for epilepsy that was discovered and developed in-house, and also includes the commercialized product Solriamfetol. Its development pipeline features candidates such as Carisbamate. Strategically, the company is expanding into new therapeutic areas, notably oncology through the development of a Radiopharmaceutical Therapy (RPT) portfolio, and is advancing digital healthcare solutions, including an AI-driven platform for epilepsy management. The company operates as a fully integrated global entity, managing the entire value chain from drug discovery to commercialization.

Recent filings

Filing Released Lang Actions
기업설명회(IR)개최(안내공시)
Investor Presentation Classification · 75% confidence The document is an official corporate disclosure announcing the scheduling and details of a 기업설명회(IR) (Investor Relations presentation) for institutional investors, including date, venue, agenda, and related web link. It is not the actual financial report or presentation materials but is clearly an Investor Relations event notice. Under our taxonomy, this falls under Investor Presentation (IP).
2026-05-19 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is titled “분기보고서” and covers the period 2026-01-01 to 2026-03-31, submitted to the Financial Services Commission and the Korea Exchange. It contains detailed financial tables, business overview, risk management, and other substantive content typical of a quarterly/interim statutory filing. It is the full interim report itself (not merely an announcement), therefore it should be classified as an Interim/Quarterly Report (IR). Q1 2026
2026-05-15 Korean
연결재무제표기준영업(잠정)실적(공정공시)
Interim / Quarterly Report Classification · 95% confidence The document is a disclosure of preliminary consolidated financial results for the first quarter of 2026, including sales, operating profit, and net income figures compared to previous periods. It mentions that the results are provisional and subject to external auditor review. The document also references a conference call event for the 1Q 2026 earnings announcement. The content includes actual financial data and analysis for a quarterly period, which fits the definition of an Interim / Quarterly Report (IR). The document length is 2514 characters, which is relatively short but contains substantive financial data, not just an announcement or certification. Therefore, it is classified as an Interim / Quarterly Report (IR).
2026-05-07 Korean
기업설명회(IR)개최(안내공시)
Regulatory Filings Classification · 95% confidence The document is an announcement for an upcoming Investor Relations (IR) event, specifically a conference call to discuss the company's preliminary Q1 2026 financial results and R&D session. It includes details such as date, time, participants, and how the event will be conducted. The document is short (735 characters) and does not contain actual financial data or detailed financial statements. It states that presentation materials will be posted on the company's website on the day of the event. Therefore, this is not the actual financial report or earnings release but an announcement about the IR event. According to the filing definitions, such announcements fall under Investor Presentation (IP) if they include detailed presentations, but since this is an announcement of the event and materials to be posted later, it fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about the IR event and not the presentation itself or the earnings release.
2026-05-04 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 90% confidence The document is a "주식등의 대량보유상황보고서(약식)" – a Large Shareholding Report filed by the National Pension Service under Korea’s Capital Market Act, detailing its shareholdings and a change in percentage (e.g., drop of 1.03%). It is a notification of significant share ownership changes (threshold crossing). This matches our “Major Shareholding Notification” category (Code: MRQ).
2026-04-01 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 90% confidence The document is a Korean statutory ownership report titled “임원ㆍ주요주주 특정증권등 소유상황보고서,” filed with the Financial Services Commission and Korea Exchange. It details shareholdings and transaction amounts by an insider (executive/major shareholder) and specific changes in stock ownership. This matches the definition for “Director’s Dealing” (DIRS), which covers insider share transaction disclosures.
2026-03-31 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.